Phase I
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its MELANI-01 trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
Pfizer and BioNTech indicate that this data, along with preclinical data and additional data being generated, will be leveraged to choose a dose level and pick the best vaccine candidate out of the several being evaluated.
INO-4800 is one of the experimental vaccines included in the U.S. government’s Operation Warp Speed that has a goal of having a vaccine available by January 2021.
PRESS RELEASES